ReviewMolecular genetics & genomic medicine2026
Phenotypic Refinement of ESAM-Related Tight-Junctionopathy: Novel Genetic and Ocular Findings and Literature Review.
Review in Molecular genetics & genomic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Phenotypic Refinement of ESAM-Related Tight-Junctionopathy: Novel Genetic and Ocular Findings and Literature Review.Molecular genetics & genomic medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundEndothelial cell-selective adhesion molecule (ESAM) is a tight junction protein essential for blood-brain barrier integrity and angiogenesis. Bi-allelic loss-of-function variants in ESAM cause NEDIHSS ("Neurodevelopmental disorder with intracranial hemorrhage, seizures, and spasticity"), a neurodevelopmental/neurovascular disorder with antenatal/neonatal onset, characterized by global developmental delay/intellectual disability (GDD/ID), epilepsy, spasticity, ventriculomegaly, and intracranial hemorrhages. Ocular involvement, particularly retinal vascular anomalies, has been variably reported.
methodsA multidisciplinary team of pediatric neurologists, ophthalmologists, and clinical geneticists evaluated the proband through clinical assessment, neuro/ocular imaging, and whole-exome sequencing.
resultsWe describe a 3-year-old male from consanguineous Albanian parents carrying a novel homozygous splice-site ESAM variant (c.70+1G>T). He presented with GDD, seizures, and brain imaging abnormalities consistent with NEDIHSS. Remarkably, bilateral optic nerve hypoplasia, esotropia, retinal detachment, absent electroretinogram response, and structural eye anomalies, including left eyeball hypoplasia and iris displacement, were observed. Review of our and previous cases indicates that 45% (10/22) of NEDIHSS individuals present ocular manifestations, mainly retinal vascular defects, reinforcing the emerging role of ESAM in retinal endothelial integrity.
conclusionsThis case broadens the mutational and clinical spectrum of ESAM-related disease, underscores the need for detailed ocular evaluations in NEDIHSS, and supports inclusion of retinal anomalies within its core phenotype.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.